Orthopedic oncologists share evolving strategies for diagnosing and managing tenosynovial giant cell tumor, weighing surgery, systemic therapy, and active surveillance.
Back
Clinical Decision-Making, MOTION Trial Data, and Long-Term Management Considerations in Tenosynovial Giant Cell Tumor
Two orthopedic oncologists discuss classifying localized vs diffuse tenosynovial giant cell tumor, efficacy and safety data from the phase 3 MOTION trial, comparison of vimseltinib and pexidartinib, patient-reported outcomes, and multidisciplinary sequencing of systemic therapy and surgery.
Clinical Decision-Making, MOTION Trial Data, and Long-Term Management Considerations in Tenosynovial Giant Cell Tumor
Episodes
All
All
MOTION Trial data show vimeceltab shrinks tumors and eases symptoms with manageable side effects, no major liver-toxicity signal, and flexible dosing options.
Experts weigh staying on pexidartinib when it works, compare vimseltinib nuances, and highlight PROMIS plus patient feedback to guide personalized care.
TGCT patients navigate delayed diagnoses and complex choices; expert teams align surgery and systemic therapy early to reduce recurrence and improve trust.
Explore how neoadjuvant therapy guides TGCT surgery timing, side-effect tradeoffs, and team-based decision-making for locally advanced disease without rushing into operations.
Advertisement
Advertisement
Trending on OncLive
1
Earlier CAR T-Cell Therapy Use Highlights Sequencing and Access Considerations in Myeloma
2
CDK4/6 Inhibitors Anchor First-Line Metastatic Breast Cancer Care, But Oral SERDs May Fall Short
3
Dr Fradley on Real-World Atrial Fibrillation and Cardiovascular Outcomes in CLL
4
Real-World, First-Line IO-Based Combos Are Associated With Improved OS vs TKI Monotherapy in Advanced RCC
5